MOLN Earnings

MOLN reported its FY2025Q3 earnings on 2025-10-30, showcasing a revenue of against an estimate of , resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.46 by 0%. The stock experienced a 6.2% price change on the earnings day and a 10.14% change over the next five days, reflecting market reactions to the results.

Following MOLN's FY2025Q3 earnings announcement on 2025-10-30, the stock price moved by 6.2% on the day of the release. Over the subsequent five days, it saw a 10.14% change. Historically, MOLN's stock price tends to shift by an average of -0.39% in the 10 days leading up to earnings and -5.29% in the 10 days following, providing insight into potential market.

For , analysts estimate MOLN's annual revenue to reach , while the EPS is projected at -0.37. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates revised upward by 15.17% over the past three months, indicating analyst expectation in the company's performance.

The correlation between MOLN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved revised upward by 15.17%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, MOLN's stock price typically moves by -0.39% in the 10 days before its earnings and -5.29% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -0.37 and revenue of .

The earnings call reveals several challenges: revenue decline due to the end of the Novartis collaboration, cash burn, and significant risks in securing isotope supply, regulatory approvals, and clinical trials. The lack of a shareholder return plan and strategic misalignment with Novartis further weigh on sentiment. Although the cash position is stable, the reliance on external funding and competitive pressures add uncertainty. The Q&A section highlighted management's vague responses, particularly regarding clinical data timelines, adding to the negative sentiment. These factors collectively suggest a negative stock price movement in the short term.